Cellectar Biosciences, Inc. (CLRB) surged 24.03 percent to $3.51 after gaining $0.68 on Tuesday, following the announcement of updated and mature clinical trial results for its cancer therapy candidate.
The stock is currently trading at $3.51, compared to a previous close of $2.83 on the Nasdaq. It opened at $4.50 and traded between $3.43 and $4.70 during the session, with volume reaching 45.74 million shares.
Following positive 12-month follow-up data from its Phase 2b CLOVER WaM trial, which showed high response rates and durable efficacy for iopofosine I 131 in heavily pretreated patients, strengthening its case for potential accelerated regulatory approval.
The stock has traded between $2.43 and $20.70 over the past 52 weeks.
For comments and feedback contact: editorial@rttnews.com
Business News
May 08, 2026 15:50 ET Manufacturing and services sector survey results and labor market data from main economies were the highlight on the economics news front this week. Factory orders and jobs report dominated the news flow in the U.S. Similarly, industrial production data from German garnered attention in Europe. In Asia, purchasing managers’ survey results from China and the central bank decision from Australia were in focus.